SNOA possible playout, Trending, momentum play, if it holds and wins 0.22 then will break out to 0.41, not financial advice.
Long
Sonoma Pharmaceuticals, Inc.
No trades
No trades
Compare with Sonoma Pharmaceuticals, Inc.
−1.22 USD
−3.17 M USD
19.53 M USD
4.77 M
Last report date
Aug 6, 2026
Report period
Q1 2026
EPS
0.02 USD
Revenue
6.41 M USD
Details
Sector
Industry
CEO
Amy M. Trombly
Website
Headquarters
Boulder
Founded
1999
IPO date
Jan 26, 2007
ISIN
US83558L3033
CUSIP
83558L303
FIGI
BBG000M75YR0
Identifiers
ISIN US83558L3033
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. Its products are used for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
Long
SNOA bullishThis stock seems to be gaining some bullish volume and the structure looks ready to shoot up.
Long
$SNOA upside potential Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatological conditions, wound care, animal health care, eye care, nasal care and oral care.
Long
mid term 3,700%Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally.
Long
$SNOABUY AND SELL SETUP
This one is more of a longer term investment.
As it shot up and retraced back down, we're sitting within golden pocket boundary.
I would start buying and buying the dips to average out my price.
Always remember, time is your best friend!
Long
Long
SNOA: $4.35 | Sold Out Shares & Under Valuedwith new products addressing aesthetic industry should recover when volume
starts to kick in
Sonoma's Harsh Treatments It looks like maybe NASDAQ:SNOA has taken a slide past the industry's watchful eye with this one being so oversold... It may be going under, but it's in California, and Arnold likes those kinds of things. I think this stock will try to regain some ground; mostly because of it's insider buys. So
Long
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of SNOA is 1.44 USD — it has increased by 15.20% in the past 24 hours. Watch Sonoma Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sonoma Pharmaceuticals, Inc. stocks are traded under the ticker SNOA.
SNOA stock has risen by 28.57% compared to the previous week, the month change is a 19.01% rise, over the last year Sonoma Pharmaceuticals, Inc. has showed a −52.48% decrease.
SNOA reached its all-time high on Jul 17, 2007 with the price of 72,323.37 USD, and its all-time low was 0.85 USD and was reached on Apr 24, 2026. View more price dynamics on SNOA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SNOA stock is 17.89% volatile and has beta coefficient of 2.28. Track Sonoma Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sonoma Pharmaceuticals, Inc. there?
Today Sonoma Pharmaceuticals, Inc. has the market capitalization of 6.90 M, it has decreased by −1.72% over the last week.
Yes, you can track Sonoma Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Sonoma Pharmaceuticals, Inc. is going to release the next earnings report on Nov 16, 2026. Keep track of upcoming events with our Earnings Calendar.
SNOA earnings for the last quarter are 0.02 USD per share, whereas the estimation was −0.30 USD resulting in a 105.01% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Sonoma Pharmaceuticals, Inc. earnings.
Sonoma Pharmaceuticals, Inc. revenue for the last quarter amounts to 6.41 M USD, despite the estimated figure of 4.99 M USD. In the next quarter, revenue is expected to reach 5.29 M USD.
SNOA net income for the last quarter is −330.00 K USD, while the quarter before that showed −581.00 K USD of net income which accounts for 0.00% change. Track more Sonoma Pharmaceuticals, Inc. financial stats to get the full picture.
No, SNOA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 9, 2026, the company has 259 employees. See our rating of the largest employees — is Sonoma Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sonoma Pharmaceuticals, Inc. EBITDA is −1.27 M USD, and current EBITDA margin is −11.89%. See more stats in Sonoma Pharmaceuticals, Inc. financial statements.
Like other stocks, SNOA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sonoma Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sonoma Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sonoma Pharmaceuticals, Inc. stock shows the sell signal. See more of Sonoma Pharmaceuticals, Inc. technicals for a more comprehensive analysis.